The main focus of Immunethep has been the development a broad-spectrum antibacterial vaccine that is now ready to start human clinical trials.
With the breakout of the Covid-19 pandemic, Immunethep decided to put its capabilities and knowledge to find new solutions that could help to stop this disease.
We are addressing Covid-19 twofold:
1) The knowledge gathered with the process of vaccine development allows us to start the assays for the development of a COVID-19 vaccine. This vaccine is designed to potentiate lung immunity to the virus. This vaccine has a dual action. It aims to induce the production of specific anti-SARS-CoV-2 neutralizing antibodies and also to enhance our natural ability to fight viral infections.
2) Recent evidences show that up to 50% of fatal cases associated with SARS-CoV-2 infection are due to opportunistic infections caused by multi-drug resistant bacteria. Taking in account that vaccinating those patients for SARS-CoV-2 wouldn’t produce a timely effective response, Immunethep is developing a monoclonal antibody-based therapy to treat these opportunistic bacterial infections.
On the one hand, the vaccine will allow the prevention of disease and avoid human-tohuman transmission and, on the other hand, the monoclonal antibodies will ameliorate the symptoms of already infected patients that could reduce significantly the number of fatal cases amongst the COVID-19 patients.